|
Route 22 West Somerville, NJ 08876 NJ Tel. 908-218-0707 Fax 908-218-2471 |
Type: Subsidiary
On the web:
http://www.omrix.com
Omrix Biopharmaceuticals helps keep blood in its place in the operating room. The company develops biosealants derived from human plasma to control bleeding during surgical procedures. The biosealants contain naturally occurring proteins that clot and adhere to tissue. Johnson & Johnson's Ethicon subsidiary markets and distributes these products under the names Evicel in the US and Quixil in Europe. Omrix's Evithrom thrombin product was developed with Ethicon primarily for neurosurgery. The FDA has approved both for hemostasis (minimizing blood loss) during surgery. Omrix was acquired by Johnson & Johnson in 2008 and became part of the Ethicon division.
Officers:
Chairman: Larry Ellberger
CEO and Director: Robert Taub
President and COO: Nissim Mashiach
Competitors:
Baxter International
CSL Behring
Haemacure
